Biotech · Private company
Cassiopea SpA
Track this companyFree. Adds Cassiopea SpA to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- CB-03-01 cream, 1%Phase 3 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- Clascoterone 5% solutionPhase 3 · Alopecia, AndrogeneticClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle creamPhase 3 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle solutionPhase 3 · Alopecia, AndrogeneticClinicalTrials.gov · fetched Nov 12, 2026
- cortexolone 17α-propionatePhase 2 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)PHASE3 · COMPLETED · started Aug 17, 2023ClinicalTrials.gov NCT05914805 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair LossPHASE3 · COMPLETED · started Jun 21, 2023ClinicalTrials.gov NCT05910450 · fetched Nov 12, 2026
- An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne VulgarisPHASE2 · COMPLETED · started Oct 28, 2016ClinicalTrials.gov NCT02720627 · fetched Nov 12, 2026
- An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne VulgarisPHASE3 · COMPLETED · started Mar 9, 2016ClinicalTrials.gov NCT02682264 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)PHASE3 · COMPLETED · started Jan 21, 2016ClinicalTrials.gov NCT02608450 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)PHASE3 · COMPLETED · started Nov 16, 2015ClinicalTrials.gov NCT02608476 · fetched Nov 12, 2026